Skip to main content

Table 3 Compliance and persistence measures of users experienced to disease-modifying agents

From: Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

 

Fingolimod

Interferon beta-1b

Intramuscular interferon beta-1a

Subcutaneous interferon beta-1a

Glatiramer acetate

 

N=152

N=35

N=66

N=98

N=115

   

p-value

 

p-value

 

p-value

 

p-value

PDC: mean (SD)

0.83 (0.23)

0.61 (0.30)

0.0002

0.67 (0.32)

0.0004

0.68 (0.31)

0.0001

0.73 (0.30)

0.0040

PDC Categories (%)

         

 0-<0.2

4.61

17.14

0.0009

9.09

0.0002

10.20

0.0002

6.09

0.0003

 0.2-<0.4

3.95

8.57

 

22.73

 

11.22

 

11.30

 

 0.4-<0.6

2.63

11.43

 

4.55

 

12.24

 

13.91

 

 0.6-<0.8

15.13

22.86

 

10.61

 

18.37

 

7.83

 

 0.8-1

73.68

40.00

 

53.03

 

47.96

 

60.87

 

MPR: mean (SD)

0.92 (0.08)

0.82 (0.18)

0.0066

0.88 (0.13)

0.0287

0.84 (0.19)

0.0004

0.89 (0.16)

0.0602

MPR Categories (%)

  

0.0001

 

0.0069

 

0.0004

 

0.0106

 0-<0.2

0.00

0.00

 

0.00

 

1.10

 

0.93

 

 0.2-<0.4

0.00

3.33

 

0.00

 

3.30

 

1.85

 

 0.4-<0.6

0.00

10.00

 

5.00

 

5.49

 

5.56

 

 0.6-<0.8

9.52

16.67

 

16.67

 

18.68

 

6.48

 

 0.8-1

90.48

70.00

 

78.33

 

71.43

 

85.19

 

Persistence (<60 day gap) (%)

74.34

42.86

0.0003

53.03

0.0020

54.08

0.0009

62.61

0.0396

Persistent days (days till first 60-day gap) (%)

         

 No gap

74.34

42.86

 

53.03

 

54.08

 

62.61

 

 1-90

6.58

22.86

 

15.15

 

19.39

 

12.17

 

 91-180

4.61

5.71

 

21.21

 

10.20

 

13.91

 

 181-270

9.21

17.14

 

6.06

 

10.20

 

6.96

 

 270+

5.26

11.43

 

4.55

 

6.12

 

4.35

 

Switched to other DMTs after discontinuation (%)

4.61

11.43

0.1219

13.64

0.0188

9.18

0.1488

13.04

0.0130

  1. P-values based on comparison with fingolimod cohort, using Chi-square tests for categorical variables and Student’s t-tests for continuous variables.
  2. DMT: disease-modifying therapy. SD: standard deviation. PDC: proportion of days covered. MPR: medication procession ratio.